Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 28;14(7):2317.
doi: 10.3390/jcm14072317.

Prognostic Impact of Chronic Kidney Disease After Percutaneous Coronary Intervention with Drug-Coated Balloons

Tetsuya Takahashi  1 , Tetsu Watanabe  2 , Mashu Toyoshima  1 , Wataru Katawaki  1 , Taku Toshima  1 , Yu Kumagai  1 , Tamon Yamanaka  1 , Masafumi Watanabe  2
Affiliations

Prognostic Impact of Chronic Kidney Disease After Percutaneous Coronary Intervention with Drug-Coated Balloons

Tetsuya Takahashi et al. J Clin Med. .

Abstract

Background: A drug-coated balloon (DCB) is an emerging treatment technology for percutaneous coronary intervention (PCI). However, the prognostic factors of PCI with a DCB remain fully determined. Chronic kidney disease (CKD) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD) who underwent PCI. The aim of this present study was to clarify the impact of CKD on prognosis in CAD patients who underwent PCI with a DCB. Methods: We enrolled 252 consecutive patients with CAD who underwent PCI with a DCB from 2015 to 2023. The endpoints of this study were composite events including all-cause death, myocardial infarction, target vessel revascularization, stroke, and major bleeding. Results: The prevalence rate of CKD was 48%. Patients with CKD were older and had higher prevalence of hypertension and diabetes mellitus than those without. Kaplan-Meier analysis revealed a significantly higher composite event rate in patients with CKD (log-rank test, p = 0.003). In the multivariate Cox proportional hazards analysis, CKD was independently associated with composite events after adjusting for confounding factors (adjusted hazard ratio 1.985, 95% confidence intervals 1.157-3.406, p = 0.013), mainly driven by all-cause deaths. Conclusions: CKD was associated with unfavorable outcomes in CAD patients who underwent PCI with a DCB.

Keywords: chronic kidney disease; drug-coated balloon; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Cumulative incidence of composite events according to CKD status. CKD, chronic kidney disease.
Figure 2
Figure 2
Univariate and multivariate Cox proportional hazard regression analyses for composite events according to CKD status. CKD, chronic kidney disease.
Figure 3
Figure 3
Cumulative incidence of (A) all-cause death, (B) cardiovascular death, (C) any myocardial infarction, (D) target vessel revascularization, (E) stroke, and (F) bleeding according to CKD status. CKD, chronic kidney disease.
Figure 3
Figure 3
Cumulative incidence of (A) all-cause death, (B) cardiovascular death, (C) any myocardial infarction, (D) target vessel revascularization, (E) stroke, and (F) bleeding according to CKD status. CKD, chronic kidney disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Scheller B., Hehrlein C., Bocksch W., Rutsch W., Haghi D., Dietz U., Böhm M., Speck U. Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter. N. Engl. J. Med. 2006;355:2113–2124. doi: 10.1056/NEJMoa061254. - DOI - PubMed
    1. Jeger R.V., Farah A., Ohlow M.-A., Mangner N., Möbius-Winkler S., Leibundgut G., Weilenmann D., Wöhrle J., Richter S., Schreiber M., et al. Drug-Coated Balloons for Small Coronary Artery Disease (BASKET-SMALL 2): An Open-Label Randomised Non-Inferiority Trial. Lancet. 2018;392:849–856. doi: 10.1016/S0140-6736(18)31719-7. - DOI - PubMed
    1. Jeger R.V., Farah A., Ohlow M.-A., Mangner N., Möbius-Winkler S., Weilenmann D., Wöhrle J., Stachel G., Markovic S., Leibundgut G., et al. Long-Term Efficacy and Safety of Drug-Coated Balloons versus Drug-Eluting Stents for Small Coronary Artery Disease (BASKET-SMALL 2): 3-Year Follow-up of a Randomised, Non-Inferiority Trial. Lancet. 2020;396:1504–1510. doi: 10.1016/S0140-6736(20)32173-5. - DOI - PubMed
    1. Shin E.S., Jun E.J., Kim S., Kim B., Kim T.H., Sohn C.B., Her A.Y., Park Y., Cho J.R., Jeong Y.H., et al. Clinical Impact of Drug-Coated Balloon–Based Percutaneous Coronary Intervention in Patients with Multivessel Coronary Artery Disease. JACC Cardiovasc. Interv. 2023;16:292–299. doi: 10.1016/j.jcin.2022.10.049. - DOI - PubMed
    1. Gitto M., Sticchi A., Chiarito M., Novelli L., Leone P.P., Mincione G., Oliva A., Condello F., Rossi M.L., Regazzoli D., et al. Drug-Coated Balloon Angioplasty for de Novo Lesions on the Left Anterior Descending Artery. Circ. Cardiovasc. Interv. 2023;16:E013232. doi: 10.1161/CIRCINTERVENTIONS.123.013232. - DOI - PubMed

LinkOut - more resources